The global impact of Precision Medicine Group.
As it happens.
Impact, observations, and insights on the evolving healthcare landscape.
Expert community unites leaders from early clinical development through global commercialization to discuss most pressing topics in biopharma and help innovators bring novel treatments to life
BETHESDA, MD., November 3, 2025 — Precision Medicine Group (Precision), a leading provider of next-generation drug development, CRO and commercialization services, today announced the launch of Institute@Precision, an expert community forum where Precision’s scientists, physicians, regulators, commercial leaders, clients, and global experts convene to address the most pressing challenges in biopharma. Each quarter, Precision will engage global thought leaders on focused topics impacting the industry, offering actionable insights that help innovators anticipate change, adapt strategy and accelerate scientific breakthroughs. (more…)
BETHESDA, MD., September 16, 2025 — Precision Medicine Group (Precision), a leading provider of next-generation drug development, CRO and commercialization services, today announced the appointment of Tracey Leahy as the company’s Chief People Officer (CPO), effective immediately. Ms. Leahy will be aligning workforce strategies with business goals and is responsible for all aspects of Precision’s Human Resources (HR) function, including talent acquisition and management, total rewards, learning and development, and HR operations. (more…)
Precision Medicine Group Names Pharma Services Innovator, Eric Hodgins, as Chief Information and Technology Officer
Industry veteran with a 30-year track record in building award-winning clinical and commercial technologies, Hodgins will focus on developing and enriching transformative technologies across Precision’s R&D and commercial services
BETHESDA, Md., April 16, 2025 – Precision Medicine Group (Precision), a leading provider of next-generation drug development, CRO and commercialization services, today announced the appointment of Eric Hodgins as the company’s Chief Information and Technology Officer, overseeing all of the company’s technology assets. (more…)
Our CEO, Margaret Keegan, is featured in the December issue of Pharmaceutical Executive candidly discussing the future of clinical development, the changing commercialization sector and the manufacturing of tomorrow’s medicines.
(more…)
Karl Deonanan appointed Chief Financial Officer
Matt DeZee named to newly established role, Chief Transformation and Strategy Officer
Bethesda, Md., October 23, 2024—Precision Medicine Group (Precision), a leading next-generation provider of drug development and commercialization services, today announced key leadership changes to support its next phase of growth. This includes the appointment of Karl Deonanan as Chief Financial Officer (CFO). Mr. Deonanan succeeds Matt DeZee, who has served as CFO of Precision since 2020 and will be transitioning to the newly created role of Chief Transformation and Strategy Officer (CTSO), effective immediately.
— Founding CEO Mark Clein named Executive Chairman; Mr. Clein and co-founder Ethan Leder to continue as Board Directors —
BETHESDA, MD., October 1, 2024 – Precision Medicine Group (Precision), a leading next-generation provider of drug development and commercialization services, today announced the appointment of Margaret Keegan as Chief Executive Officer (CEO) and member of the Board of Directors, effective immediately. Ms. Keegan succeeds Mark Clein, who is assuming the role of Executive Chairman. Mr. Clein co-founded Precision in 2012 as CEO and, together with co-founder Ethan Leder, purpose-built Precision to capitalize on the scientific and technological innovations that are transforming drug development and enabling widespread access to new, breakthrough therapies. Mr. Leder formerly served as Executive Chairman and will remain a member of the Board of Directors.
Simon Fleming has joined the Precision leadership team as Executive Vice President, Clinical Solutions. With over 30 years of experience leading global functions at a large CRO, Simon’s invaluable expertise will strengthen Precision across multiple fronts. He brings an impressive track record of performance, technical skills, and passion for aligning teams to drive research forward. We are confident Simon will make immediate strategic contributions as we continue advancing and accelerating the development of life-changing innovations.
This article was originally published on This Month in Transformative Medicine on October 17, 2023
The current standard of cancer care has saved many lives, but these methods often come with incredibly difficult side effects. Advancements in technology have brought new options to cancer care that hope to provide meaningful outcomes while minimizing the impact to the patient’s quality of life.
In this white paper Anshul Mangal, President of Project Farma (PF) & Precision ADVANCE, and Sumit Verma, Co-founder and Partner at Orchestra Life Sciences, discuss the power and potential of radioligand therapies and its impact on the treatment of a number of cancers.
In the rapidly evolving landscape of advanced therapies, allogeneic cell therapies have emerged as a promising avenue for addressing various disorders, including hematological malignancies, neurological conditions, and autoimmune or inflammatory diseases. With a number of clinical trials underway to evaluate their efficacy, allogeneic cell therapies hold significant potential in reshaping the way we approach treating numerous diseases.
In this white paper, Anshul Mangal, President of Project Farma & Precision ADVANCE and John Khoury, Executive Vice President of Project Farma (PF), discuss the growth of the allogeneic cell therapy sector and its impact on patient access.
The concept of optimizing CGT value propositions begs the question of what is reasonable when it comes to breakthrough science and unprecedented therapeutic solutions. Can a $5 million price tag be justified? What about $10 million?
This white paper is based on a webinar convened by PRECISIONadvisors, focusing on cell and gene therapy (CGT) pricing. The webinar featured two in-house experts from the PRECISIONadvisors Global Pricing & Market Access practice: Richard Macaulay, Senior Vice President and David Carr, Senior Director.